Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib DDI Study with Midazolam in ALK/ROS1+ Solid Tumors
NCT03420742Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of brigatinib in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Maximum Observed Plasma Concentration and 1 more. Started Jun 2019; status: completed.
02
Drugs
brigatinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03420742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420742.